Filing Flows › Pharma-Bio Serv (PBSV) › Q3 FY26 › vs Q2 FY26
Pharma-Bio Serv (PBSV) Q3 FY26 vs Q2 FY26 (quarter over quarter)
Pharma-Bio Serv's revenue fell $367K (-14%) from $2.7M in Q2 FY26 to $2.3M in Q3 FY26.
Pharma-Bio Serv, Q3 FY26: revenue $2.3M (+19% year over year), operating margin -3.1%, net loss $14K, operating cash flow $61K. The chart draws each line against Q2 FY26, the increases inside each band.
Margins
| Q3 FY26 | Q2 FY26 | Change | |
|---|---|---|---|
| Free cash flow margin | 2.5% | -13.6% | +16.1 pts |
Every line
| Line | Q3 FY26 | Q2 FY26 | Change | % |
|---|---|---|---|---|
| Revenue | $2.3M | $2.7M | −$367K | -14% |
| Other income, net | $61K | $95K | −$34K | -36% |
| Net loss | $14K | −$233K | $247K | — |
| Costs & expenses | $2.4M | $2.8M | −$387K | -14% |
| Operating costs | $2.4M | $2.6M | −$150K | -6% |
| Income tax | $3K | $6K | −$3K | -51% |
| Cost of revenue | $1.6M | $1.8M | −$157K | -9% |
| Operating expenses | $764K | $757K | $6K | +0.8% |
| Operating cash sources | $75K | −$598K | $673K | — |
| Depreciation & amortization | $14K | $14K | $45 | +0.3% |
| Share-based compensation | $9K | $9K | $1 | 0% |
| Working capital & other | $53K | −$621K | $673K | — |
| Net loss absorbed | $14K | −$233K | $247K | — |
| Operating cash flow | $61K | −$365K | $426K | — |
| Free cash flow (OCF − capex) | $60K | −$368K | $427K | — |
| Capital expenditures | $1K | $2K | −$1K | -40% |
Questions
How much did Pharma-Bio Serv's revenue grow quarter over quarter in Q3 FY26?
Pharma-Bio Serv's revenue fell $367K (-14%) from $2.7M in Q2 FY26 to $2.3M in Q3 FY26.